Onyia Jude 4
4 · NEUROCRINE BIOSCIENCES INC · Filed Dec 2, 2025
Insider Transaction Report
Form 4
Onyia Jude
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2025-11-29+4,426→ 18,129 total - Tax Payment
Common Stock
2025-11-29$152.16/sh−2,248$342,056→ 15,881 total - Exercise/Conversion
Restricted Stock Unit
2025-11-29−4,426→ 0 total→ Common Stock (4,426 underlying)
Footnotes (3)
- [F1]Shares withheld by Neurocrine Biosciences, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.
- [F2]Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock.
- [F3]This RSU was granted to the Reporting Person on November 29, 2021. In accordance with the terms of the RSU, the award vested as to 4,425 shares on November 29, 2022, vested as to 4,425 shares on November 29, 2023, vested as to 4,426 shares on November 29, 2024, and vested as to 4,426 shares on November 29, 2025, subject to the terms and conditions of the award.